Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses. From a Danish population-based nationwide cohort of HIV patients we identified the individuals who initiated a salvage regimen including raltegravir and a matched cohort of...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical epidemiology Ročník 2; číslo default; s. 145 - 151
Hlavní autori: Engsig, Frederik N, Gerstoft, Jan, Kronborg, Gitte, Larsen, Carsten S, Pedersen, Gitte, Audelin, Anne M, Jørgensen, Louise B, Obel, Niels
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: New Zealand Taylor & Francis Ltd 09.08.2010
Dove Medical Press
Predmet:
Antiretroviral drugs
Clinical medicine
Epidemiology
Immunology
Original Research
raltegravir
matched cohort
salvage regime
HIV
efficacy
ISSN:1179-1349, 1179-1349
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses. From a Danish population-based nationwide cohort of HIV patients we identified the individuals who initiated a salvage regimen including raltegravir and a matched cohort of HIV-infected patients initiating HAART for the first time. We compared these two cohorts for virological suppression, gain in CD4 count, and time to first change of initial regimen. We identified 32 raltegravir patients and 64 HIV patients who initiated HAART for the first time in the period 1 January 2006 to 1 July 2009. The virological and immunological responses in the raltegravir patients were comparable to those seen in the control cohort. No patients in the two cohorts died and no patients terminated raltegravir treatment in the observation period. Time to first change of initial regimen was considerably shorter for HAART-naïve patients. We conclude that salvage regimens including raltegravir have high effectiveness in the everyday clinical setting. The effectiveness of the regimens is comparable to that observed for patients initiating HAART for the first time. The risk of change in the salvage regimens after initiation of raltegravir is low.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1179-1349
1179-1349
DOI:10.2147/CLEP.S10478